A medication called intravenous pegloticase is used to treat patients with chronic and refractory gout in cases where other treatments have failed. The presence of too much uric acid in the blood results in the disease gout (hyperuricemia). The mechanism by which intravenous pegloticase reduces uric acid levels in the body.
To control the side effects of the medication, healthcare professionals and healthcare facilities administer intravenous pegloticase. The market for intravenous pegloticase is anticipated to grow during the forecast period as a result of rising gout disease prevalence worldwide and robust R & D pipelines.
On the market for intravenous pegloticase globally, a pandemic coronavirus is anticipated to have a significant impact. The global closure of the intravenous pegloticase market manufacturing industries has resulted in an unprecedented shift in technology and business strategy.
Due to international restrictions, there has been a disruption in the production and supply of intravenous pegloticase. Additionally, there are fewer patients seeking gout treatment in hospitals and clinics, which is having an impact on the market for intravenous pegloticase.
Intravenous pegloticase Market: Drivers and Restraints
The main factor driving the growth of the intravenous pegloticase market is anticipated to be the rising prevalence of chronic and refractory gout disease. Another important factor propelling the market for intravenous pegloticase is the strong R & D pipelines.
The market for intravenous pegloticase is expanding due to an increase in major company mergers and partnerships as well as a rise in demand for effective treatments for chronic and refractory gout. Furthermore, the market for intravenous pegloticase is likely to grow as more people become aware of and use it to treat chronic and refractory gout, particularly in emerging nations.
The market for intravenous pegloticase, however, may be constrained by several factors, including drug-related side effects, such as infusion reactions and anaphylaxis.
Numerous other negative side effects have also been documented, including gout flare-ups, nausea, contusions, chest pain from nasopharyngitis, and vomiting. Additionally, the growth of the intravenous pegloticase market is constrained by the strict regulations imposed by the authorities.
Intravenous pegloticase Market: Overview
Due to the rising prevalence of chronic and refractory gout disease among adults, the adult segment is anticipated to hold a significant share of the intravenous pegloticase market. The market for intravenous pegloticase is anticipated to be dominated by the chronic gout disease segment based on the indication.
Due to the higher patient flow in hospitals, hospital pharmacies are anticipated to be the most lucrative segment in the global intravenous pegloticase market based on the distribution channel.
Intravenous pegloticase Market: Region-wise Outlook
Due to improvements in the treatment of gout diseases and an increase in the prevalence of chronic and refractory gout disease in the region, North America is predicted to dominate the global intravenous pegloticase market. Europe is anticipated to follow North America in terms of drug adoption due to the latter’s higher rates there.
Due to rising healthcare costs and increased awareness of intravenous pegloticase use, Asia-Pacific is anticipated to experience significant growth in the global intravenous pegloticase market throughout the forecast period. Additionally, the region’s market for intravenous pegloticase is likely to grow as a result of the expanding populations of nations like China and India.
Intravenous pegloticase Market: Key Market Participants
Some of the market participants in the global intravenous pegloticase market identified across the value chain include:
- Horizon Therapeutics
- BTG plc
- Savient Pharmaceuticals Inc
Intravenous pegloticase Market Segmentation
- Hospital pharmacies
- Retail Pharmacies
For more insights into the market, Get a Sample Copy